PURPOSE: The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC). MATERIALS AND METHODS: A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival. RESULTS: The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05). CONCLUSION: We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.
PURPOSE: The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC). MATERIALS AND METHODS: A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival. RESULTS: The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05). CONCLUSION: We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.
Authors: G Cormio; G Di Vagno; G Di Gesù; M Mastroianni; G A Melilli; A Vimercati; G Putignano; G Loverro; L Selvaggi Journal: Gynecol Obstet Invest Date: 2000 Impact factor: 2.031
Authors: B Y Karlan; R L Baldwin; E Lopez-Luevanos; L J Raffel; D Barbuto; S Narod; L D Platt Journal: Am J Obstet Gynecol Date: 1999-04 Impact factor: 8.661
Authors: J C Dalrymple; P Bannatyne; P Russell; H J Solomon; M H Tattersall; K Atkinson; J Carter; P Duval; P Elliott; M Friedlander Journal: Cancer Date: 1989-07-01 Impact factor: 6.860
Authors: L D Kowalski; A I Kanbour; F V Price; S D Finkelstein; W A Christopherson; J C Seski; G J Naus; J A Burnham; A Kanbour-Shakir; R P Edwards Journal: Cancer Date: 1997-04-15 Impact factor: 6.860
Authors: J D Bloss; S Y Liao; R E Buller; A Manetta; M L Berman; S McMeekin; L P Bloss; P J DiSaia Journal: Gynecol Oncol Date: 1993-09 Impact factor: 5.482
Authors: Skyler B Johnson; Joann I Prisciandaro; Jessica Zhou; Scott W Hadley; R Kevin Reynolds; Shruti Jolly Journal: J Appl Clin Med Phys Date: 2014-01-06 Impact factor: 2.102